The clinical-stage biotech's top- and bottom-line numbers weren't the most important thing in the first quarter.
News & Analysis: Corbus Pharmaceuticals Holdings
CRBP earnings call for the period ending March 31, 2019.
An analyst's favorable opinion of the biotech stock stirred up investors' excitement.
Which stock wins in a matchup between these two cannabinoid-focused biotechs?
A presentation reminded investors of the potential in the biotech's endocannabinoid candidates.
CRBP earnings call for the period ending December 31, 2018.
Investors have been ignoring this cannabis drug company's progress.
Does GW's head start in getting to market make it the better choice over Corbus?
The clinical-stage biotech couldn't hold on to all of the big gains it racked up on Thursday.
Find out what left investors in these three stocks feeling groovy.